FDA Reconsiders diet Pill Qnexa

The FDA is once again reconsidering approval of the trial diet pill Qnexa that it rejected last year over concerns about cognitive disorders, metabolic acidosis, increased heart rate, and

birth defects.

California-based pharmaceutical company Vivus Inc, is now asking for limited approval for its oral combination drug Qnexa, which would not include women who would potentially become pregnant. According to the company making QNexa-Vivus inc., the FDA is scheduled to make an approval decision next April. If approved, the drug could be commercially available soon after that.

Qnexa is a combination of two drugs phentermine/Topiramate, Phentermine has been used as a weight loss pill for many years and Topiramate is an ant-seizure and migraine medication. If this diet pill is approved it would be the first long term appetite suppressant weight loss pill the United States. The only other widely marketed prescription weight loss drug, orlistat — sold by prescription as Xenical and over-the-counter as Alli — works by blocking dietary fat absorption.

While many are claiming that this would be the most successful weight loss pill since Fen-Phen . For those that do not remember Fen-Phen was a combination of two separate drugs — fenfluramine and phentermine. Fenfluramine, which was linked to potentially fatal heart problems, was pulled from the market in the late 1990s.

You may also like...